ADMA [NASD]
ADMA Biologics, Inc.
Index- P/E- EPS (ttm)-0.50 Insider Own2.10% Shs Outstand195.87M Perf Week-4.35%
Market Cap414.77M Forward P/E- EPS next Y-0.14 Insider Trans0.00% Shs Float175.24M Perf Month-3.41%
Income-78.30M PEG- EPS next Q-0.07 Inst Own64.70% Short Float14.44% Perf Quarter8.79%
Sales94.00M P/S4.41 EPS this Y41.60% Inst Trans27.78% Short Ratio8.34 Perf Half Y52.31%
Book/sh0.65 P/B3.05 EPS next Y55.20% ROA-29.70% Target Price5.12 Perf Year23.75%
Cash/sh0.33 P/C5.97 EPS next 5Y- ROE-64.90% 52W Range1.01 - 2.32 Perf YTD40.43%
Dividend- P/FCF- EPS past 5Y20.40% ROI-24.70% 52W High-11.88% Beta1.00
Dividend %- Quick Ratio3.20 Sales past 5Y50.00% Gross Margin7.00% 52W Low101.98% ATR0.14
Employees527 Current Ratio7.60 Sales Q/Q81.90% Oper. Margin-68.80% RSI (14)51.35 Volatility7.61% 7.07%
OptionableYes Debt/Eq1.09 EPS Q/Q19.70% Profit Margin-83.30% Rel Volume0.42 Prev Close1.98
ShortableYes LT Debt/Eq1.09 EarningsMay 11 AMC Payout- Avg Volume3.03M Price2.04
Recom1.50 SMA200.52% SMA504.43% SMA20028.50% Volume1,099,093 Change3.03%
Nov-11-21Upgrade Raymond James Outperform → Strong Buy $5
Nov-09-21Initiated Cantor Fitzgerald Overweight $4.50
Jun-04-19Initiated Jefferies Buy $8
Apr-15-19Reiterated H.C. Wainwright Buy $10 → $13
Feb-07-19Resumed H.C. Wainwright Buy $10
Dec-11-17Reiterated Maxim Group Buy $13 → $8
Nov-14-17Upgrade Raymond James Mkt Perform → Outperform
Jan-23-17Upgrade Maxim Group Hold → Buy $13
Aug-01-16Downgrade Maxim Group Buy → Hold
Jul-25-16Reiterated Maxim Group Buy $24 → $14
May-13-15Reiterated Maxim Group Buy $18 → $24
Dec-08-14Initiated Oppenheimer Outperform $20
Dec-01-14Reiterated Maxim Group Buy $16 → $18
Jun-26-22 09:11AM  
Jun-21-22 07:00AM  
May-11-22 05:45PM  
04:05PM  
May-10-22 06:30AM  
May-04-22 08:25AM  
07:00AM  
Apr-17-22 08:59AM  
Apr-01-22 07:00AM  
Mar-25-22 07:00AM  
Mar-24-22 05:35PM  
04:05PM  
Mar-21-22 07:00AM  
Mar-07-22 04:05PM  
Mar-03-22 04:27AM  
Jan-19-22 07:00AM  
Jan-18-22 07:00AM  
Jan-17-22 04:22AM  
Jan-12-22 09:38AM  
Dec-29-21 10:53AM  
Dec-21-21 07:00AM  
Dec-10-21 11:24AM  
10:17AM  
Dec-09-21 07:00AM  
Dec-07-21 04:56PM  
Nov-17-21 07:00AM  
Nov-16-21 07:00AM  
Nov-11-21 07:49AM  
Nov-10-21 09:00PM  
05:35PM  
04:01PM  
Nov-03-21 07:00AM  
Oct-28-21 03:06PM  
Oct-27-21 05:27AM  
Oct-25-21 04:01PM  
Oct-22-21 07:00AM  
Oct-21-21 12:28PM  
09:00AM  
Oct-20-21 04:01PM  
Oct-19-21 07:00AM  
Oct-18-21 07:00AM  
Oct-04-21 07:00AM  
Oct-01-21 11:11AM  
07:00AM  
Sep-30-21 11:16AM  
Sep-29-21 02:27PM  
Sep-23-21 07:00AM  
Sep-08-21 08:08AM  
07:00AM  
Sep-02-21 07:00AM  
Aug-20-21 08:03AM  
Aug-16-21 08:27AM  
07:00AM  
Aug-12-21 12:00PM  
Aug-11-21 06:55PM  
04:05PM  
Aug-10-21 04:30PM  
Aug-09-21 07:00AM  
Aug-04-21 07:00AM  
Jul-28-21 03:03PM  
Jul-21-21 01:23AM  
Jul-20-21 07:00AM  
Jun-14-21 07:00AM  
May-26-21 07:00AM  
May-22-21 03:08AM  
May-12-21 09:00PM  
04:05PM  
02:30PM  
May-10-21 08:39AM  
May-06-21 01:27AM  
May-05-21 07:00AM  
Apr-28-21 01:54PM  
12:34PM  
08:41AM  
07:07AM  
07:00AM  
Apr-26-21 08:00AM  
Apr-21-21 11:43AM  
Apr-13-21 08:00AM  
Mar-25-21 07:30PM  
05:35PM  
04:05PM  
Mar-18-21 08:00AM  
Mar-04-21 12:30PM  
08:00AM  
Mar-03-21 08:00AM  
Feb-26-21 08:00AM  
Feb-22-21 08:00AM  
Feb-04-21 11:49PM  
Feb-01-21 08:00AM  
Jan-26-21 08:00AM  
Jan-19-21 08:00AM  
Jan-04-21 08:00AM  
Dec-21-20 11:24PM  
Dec-19-20 11:26AM  
Dec-16-20 04:15PM  
Dec-09-20 10:33AM  
08:48AM  
08:00AM  
Dec-08-20 11:35AM  
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Grossman Adam SPresident and CEOOct 25Buy1.00250,000250,0001,128,444Oct 26 07:00 AM
Grossman Adam SPresident and CEOOct 25Buy1.00100,000100,0002,137,616Oct 26 07:00 AM
LENZ BRIANEVP, CFOOct 25Buy1.0030,00030,0001,065,501Oct 26 07:00 AM
Grossman Jerrold BDirectorOct 25Buy1.00100,000100,000260,864Oct 26 07:00 AM
KWON YOUNGDirectorOct 25Buy1.00100,000100,000200,000Oct 26 07:00 AM
PERCEPTIVE ADVISORS LLC10% OwnerSep 30Sale1.12137,495153,99413,262,375Sep 30 07:27 PM
PERCEPTIVE ADVISORS LLC10% OwnerSep 29Sale1.1682,50595,70613,399,870Sep 30 07:27 PM
PERCEPTIVE ADVISORS LLC10% OwnerSep 28Sale1.2240,60349,53613,482,375Sep 30 07:27 PM
PERCEPTIVE ADVISORS LLC10% OwnerSep 27Sale1.23250,000307,50013,522,978Sep 29 07:18 PM
PERCEPTIVE ADVISORS LLC10% OwnerSep 24Sale1.26250,000315,00013,772,978Sep 29 07:18 PM
PERCEPTIVE ADVISORS LLC10% OwnerSep 23Sale1.27780,000990,60014,022,978Sep 28 04:18 PM
PERCEPTIVE ADVISORS LLC10% OwnerAug 19Sale1.24350,352434,43614,802,978Aug 19 07:58 PM
PERCEPTIVE ADVISORS LLC10% OwnerAug 18Sale1.29552,380712,57015,153,330Aug 19 07:58 PM
PERCEPTIVE ADVISORS LLC10% OwnerAug 17Sale1.35879,0921,186,77415,705,710Aug 19 07:58 PM